secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sage Therapeutics, Inc. (—)
CIK:        0001597553
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001193125-24-238425
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sage Therapeutics restructures, reduces workforce by 33%; CFO and GC to leave; new COO
--------------------------------------------------------------------------------

- Workforce cut of ~33%, including ~55% of R&D; severance charge of $26-28M in Q4 2024.
- CFO Kimi Iguchi and SVP/GC Anne Marie Cook depart effective Oct 31, 2024.
- Chris Benecchi named COO and Treasurer effective Nov 1, 2024, assuming principal financial and accounting officer roles.
- Company expects lower operating expenses and extended cash runway from reorganization and pipeline prioritization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597553/000119312524238425/0001193125-24-238425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597553/000119312524238425/d891074d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer